2-Bromo-4-Thiazolecarboxylic Acid

In the preclinical optimization of free fatty acid receptor 1 (FFA1 or GPR40) agonists aimed at 10 mg and 50 mg solid oral dosage forms for type 2 diabetes mellitus, the 2-bromo-4-thiazolecarboxylic acid intermediate is subjected to palladium(0)-catalyzed Suzuki–Miyaura cross-coupling with a range of functionalized arylboronic acids. Compliance with Good Manufacturing Practice (GMP) for this advanced intermediate is structured around ICH Q7 (Active Pharmaceutical Ingredients), with particular emphasis on Section 8.1 on raw materials and Section 12.7 on validation of reprocessing; residual palladium content is strictly controlled under ICH Q3D (Elemental Impurities) to a permitted daily exposure (PDE) of <10 µg/g for oral administration, while residual solvents such as tetrahydrofuran (THF) are limited to class 2 thresholds per ICH Q3C. The addition ratio between the 2-bromo-4-thiazolecarboxylic acid and the arylboronic acid coupling partner is held at 1.00–1.05 molar equivalents in favor of the thiazole; excess thiazole is deliberately avoided because the homocoupled bi-thiazole byproduct formed under oxidant-free Suzuki conditions co-elutes with the desired product during reverse-phase chromatography, complicating purification. The downstream manufacturing sequence takes place in a dedicated 500-L glass-lined reactor train equipped with a retreat-curve impeller, a nitrogen sparge ring, and a jacket temperature control system maintaining 65–70 °C. A degassed 2:1 THF/2 M aqueous K₂CO₃ mixture is charged, followed by 0.6 mol% Pd(PPh₃)₄ and the boronic acid; the bromothiazole acid is added as a THF solution over 45 min to mitigate exotherm-induced dehromination side reactions. After 4 h of agitation, the aqueous phase is cut and the organic layer is washed with 5% EDTA disodium solution (pH 8.5) to chelate dissolved palladium species, then brine, dried over Na₂SO₄, and filtered. Solvent swap to ethyl acetate and subsequent slow addition of n-heptane at 45 °C induces crystallization; the slurry is cooled linearly to 0 °C at a rate of 0.5 °C/min to promote uniform crystal growth, centrifuged under nitrogen, and vacuum dried at 40 °C with a nitrogen leak. The terminal product class encompasses sodium and meglumine salts of 2-arylthiazole-4-carboxylic acids, which are advanced to Phase I/II clinical trials and formulated as immediate-release tablets using dry granulation (roller compaction) with mannitol and croscarmellose sodium. A critical incompatibility is the lability of the carbon–bromine bond under alkaline conditions above pH 9.5, which results in defunctionalization; thus, the Suzuki coupling must avoid prolonged contact with hydroxide bases such as NaOH, favoring the less nucleophilic CO₃²⁻ buffer system. Light exposure accelerates debromination, compelling the use of amber glass and argon blanketing throughout the sequence.

Why the Brominated Thiazole Core Dominates SDHI Lead Optimization for Basidiomycete Control

In commercialized SDHI (succinate dehydrogenase inhibitor) programs aimed at controlling Rhizoctonia solani in rice and Sclerotinia sclerotiorum in oilseed rape, 2-bromo-4-thiazolecarboxylic acid is transformed into a methyl ester using methanol and sulfuric acid (2% w/w) at reflux for 6 h, driving the equilibrium by azeotropic removal of water with a molecular sieve layer in a Soxhlet apparatus at pilot scale. The resulting methyl ester meets the FAO relevant specification for technical material purity, minimum 98.5% by GC area normalization. Industry compliance for the entire supply chain of the formulated fungicide includes OECD GLP guidelines for physico-chemical testing (Series 100) and, prior to registration, a full toxicological profile as defined by EPA 40 CFR §158.500; the technical concentrate must be shown to contain no more than 0.1% of the mutagenic 2-bromo-4-thiazolecarboxylic acid residual through a validated LC-MS/MS method (LOQ 0.05%). The key amidation addition ratio of the methyl ester relative to 2,6-dibromo-4-(trifluoromethoxy)aniline is 1.00 ± 0.02 equivalents; an additional 5 mol% of triethylamine serves as acid scavenger for liberated HCl that would otherwise protonate the aniline and halt conversion. Downstream processing in a 2000-L glass-lined reactor involves charging toluene, the aniline, and triethylamine, heating to 110 °C, then slowly metering in the methyl ester solution over 2 h under a slow nitrogen sweep to prevent vapor-phase condensation of the ester. The reaction is held at reflux for 16–20 h with continuous water separation via a Dean–Stark trap; the progress is monitored by HPLC until residual aniline drops below 0.5 area%. After completion, the warm solution is washed with 5% aqueous HCl at 60 °C, then water, and the organic phase is dried with anhydrous sodium sulfate. Toluene is distilled under reduced pressure and replaced by methanol; the amide crystallizes at −5 °C and is isolated in a horizontal peeler centrifuge, washed with chilled methanol, and dried at 60 °C under vacuum with a rotary drum dryer. The resulting technical active ingredient (TGAI) is air-milled to D₉₀ <10 µm using a fluid-energy mill, then formulated as a 200 g/L suspension concentrate through high-shear dispersion with a Silverson 450LS inline mixer: the milling base comprising TGAI, ethylene glycol (6% w/w inert antifreeze), Morwet D-425 (3% w/w dispersant), and SAG 10 (0.5% antifoam) is passed through a bead mill with 0.6 mm yttria-stabilized zirconia beads until particle size D₅₀ <2 µm (ISO 13320:2020 laser diffraction). A structuring agent (xanthan gum, 0.2% w/w) is added under low shear to achieve a viscosity of 400–600 mPa·s at 20 s⁻¹. Terminal product formulations include also 50% water-dispersible granules, produced by spray-drying the slurry with a fluidized-bed granulator. Storage stability must be verified under CIPAC MT 46.1 at 54 °C for 14 days. The bromothiazole ester intermediate is incompatible with primary amines at temperatures above 80 °C, which can induce thiazole ring-opening side reactions; thus, the neat ester is stored under nitrogen at <5 °C. Production personnel must be protected from contact (dermal sensitization potential observed in local lymph node assay).

Within the context of hepatitis C virus (HCV) NS5A replication complex inhibitors that rely on a C2-symmetric dimeric motif, the 2-bromo-4-thiazolecarboxylic acid moiety serves as a rigid isostere of 4-aminophenylalanine, providing the necessary π-stacking interactions with the NS5A pocket. The synthetic intermediate must conform to ICH M7 (Assessment and Control of DNA Reactive Impurities) with the threshold of toxicological concern (TTC) set at ≤1.5 µg/day; because the acid is activated with HATU, the potential formation of 7-aza-1‑hydroxybenzotriazole-related mutagenic impurities is monitored by LC-TOF at a limit of 0.15% relative to the API. The addition proportion during the amide-forming step is maintained at 0.98–1.02 equivalents of the acid relative to the L‑proline‑derived amine, with activation employing 1.10 ± 0.03 equivalents of HATU and 2.5 ± 0.2 equivalents of N,N-diisopropylethylamine (DIPEA) at 0–5 °C in anhydrous DMF (water content <0.01% by KF). The process is run in a 300-L Hastelloy C-276 reactor due to the corrosive nature of the DMF/HCl/DIPEA mixture; the acid is pre-activated with HATU at 0 °C for 15 min before addition of the amine dissolved in chilled DMF. After 3 h of conversion (confirmed by TLC), the batch is quenched into a cold solution of 5% citric acid and promptly extracted with 2-methyltetrahydrofuran (2-MeTHF) containing 0.05% w/w α‑pinene as a peroxide inhibitor. The organic extract is washed sequentially with 5% sodium bicarbonate, water, and brine; then filtered through a 0.2 µm PTFE inline filter before vacuum distillation at a jacket temperature not exceeding 30 °C. The residue, after solvent swap to isopropanol, is crystallized by water addition to yield the dimer precursor with a purity >99.3% (HPLC at 210 nm). This precursor is elaborated into a pan-genotypic NS5A inhibitor, which is ultimately formulated as a 75 mg film-coated tablet using fluid-bed granulation with copovidone, microcrystalline cellulose, and croscarmellose sodium. A critical process incompatibility is the rapid hydrolysis of HATU in the presence of even trace water, leading to incomplete activation and formation of the corresponding hydroxy ester impurity; all reactors and transfer lines must be dried with isopropanol and purged with nitrogen to a dew point of −40 °C. Additionally, the 2-MeTHF solvent can form peroxides upon extended exposure to air, so continuous nitrogen blanketing and weekly peroxide testing (ASTM E299) are mandatory.

Antifungal CYP51 Inhibition Scaffolds Derived via 2-Arylthiazole-4-carboxylic Acid Motifs

In combating fluconazole-resistant Candida krusei and azole-tolerant Aspergillus fumigatus, medicinal chemistry programs have exploited the 2-bromo-4-thiazolecarboxylic acid core to generate non-nitrogenazole CYP51 inhibitors. The carboxylic group is conserved to establish a hydrogen-bond network with the enzyme’s heme propionate, while the 2-position is functionalized through a copper-free Sonogashira cross-coupling with 4-ethynylbenzonitrile. Industry compliance for this lead-optimization intermediate is non-GMP but adheres to USP <232> (Elemental Impurities – Limits) and USP <233> (Procedures) for oral candidate pre-IND toxicology studies; the limit for palladium is set at <10 µg/g and for nickel at <20 µg/g, as determined by ICP-MS after microwave digestion. The addition ratio in the Sonogashira step requires a large excess of the terminal alkyne: 1.0 molar equivalent of 2-bromo-4-thiazolecarboxylic acid to 1.8 ± 0.1 equivalents of 4-ethynylbenzonitrile, together with 2 mol% Pd(PhCN)₂Cl₂, 4 mol% P(t-Bu)₃, and 2.0 equivalents of dry 1,4-diazabicyclo[2.2.2]octane (DABCO) in degassed dimethyl sulfoxide at 50 °C. The excess volatile alkyne is recovered post-reaction by thin-film evaporation (45 °C, 5 mbar) and reused after vacuum distillation. The downstream process proceeds in a 100-L Hastelloy reactor under argon; the mixture is filtered through a Celite pad and acidified with cold 1 N HCl to pH 3–3.5, at which point the product precipitates as a tan solid. The crude is purified by flash chromatography on silica gel (mobile phase: heptane : ethyl acetate 2:1 with 0.5% acetic acid) to afford the 2-alkynyl-thiazole acid in 89–92% yield and >98% purity. The purified intermediate subsequently undergoes a copper(I)-catalyzed azide‑alkyne cycloaddition (CuAAC) with benzyl azide to install a 1,2,3-triazole ring; here, CuSO₄/sodium ascorbate in t-BuOH/H₂O is employed, and residual copper is scavenged by treatment with QuadraPure® benzylamine resin to achieve <15 µg Cu/g. The final antifungal candidate is developed as a 2% w/w topical cream for vulvovaginal candidiasis, formulated with cetyl alcohol, stearyl alcohol, and polysorbate 60 to create an oil-in-water emulsion, or as an oral suspension containing microcrystalline cellulose and sucrose. This pathway avoids direct amidation of the carboxylic acid with basic amines because the presence of thiazole nitrogen adjacent to the acid catalyzes decarboxylation above 80 °C; therefore, active ester (N-hydroxysuccinimide ester) pre-generation is mandatory for peptide coupling. Under storage, the bromo acid monomer exhibits dimerization via acid anhydride formation in the presence of DCC or EDC coupling reagents if moisture is not rigorously excluded, thus freshly prepared batches are used within 72 h after release.

In the design of mixed-linker metal–organic frameworks (MOFs) for landfill gas upgrading (CO₂/CH₄ selectivity), 2-bromo-4-thiazolecarboxylic acid is introduced as a heterocyclic co-linker alongside terephthalic acid to impart local polarity and halogen-bonding sites in the framework. No formal regulatory standard governs the MOF synthesis procedure itself, but the material is characterized in accordance with ISO 9277:2010 for BET specific surface area (N₂ adsorption at 77 K, 20-point isotherm, sample outgassed at 120 °C for 12 h until a pressure rise rate of <0.5 Pa/min) and ISO 15901-2:2006 for mesopore size distribution using DFT kernel files. The addition ratio in the solvothermal charge is fixed at a total linker (2-bromo-4-thiazolecarboxylic acid + terephthalic acid) to metal salt of 1.0:1.1, with the thiazole linker comprising 25 mol% of the linker mixture; the slight stoichiometric excess of Zn(NO₃)₂·4H₂O (1.1 eq) over the total carboxylate donors prevents residual free linker that could poison active sites. The downstream process scaling is executed in a 500-mL Teflon-lined stainless steel autoclave (Parr Instrument) with a burst disk rated to 200 bar; the salts and linkers are dissolved in a mixture of DMF/EtOH/deionized water (3:1:1, v/v/v) and sonicated for 20 min under argon sparge to prevent defective nucleation. The sealed autoclave is heated to 110 °C at a ramp rate of 2 °C/min, held for 48 h under autogenous pressure (ca. 3 bar), then slowly cooled to 25 °C at 0.5 °C/min. The crystalline MOF is isolated by centrifugation, washed with DMF (3×) and methanol (3×), and finally subjected to Soxhlet extraction with methanol for 24 h to remove high-boiling DMF occluded within the cages. Activation is performed under dynamic vacuum at 100 °C for 16 h; temperatures above 140 °C cause thermal debromination and framework collapse, as evidenced by a 12% loss of BET area in control experiments. The final product class is a microcrystalline powder with a Langmuir surface area of 1280–1380 m²/g and a CO₂ uptake of 3.4 mmol/g at 1 bar (298 K), intended for use in pressure swing adsorption columns packed with structured monoliths. The brominated thiazole moiety is incompatible with ammonia-based post-synthetic modifications because nucleophilic displacement of bromine can occur under solvent-free conditions at 80 °C, altering pore geometry; therefore, grafting reactions are limited to azide-alkyne click chemistry on the bromine-free partner.

If the Thiazole-4-carboxylic Acid is Integrated into β-Secretase (BACE1) Inhibitor Backbones

In the development of non-peptide β-secretase (BACE1) inhibitors targeting the treatment of mild cognitive impairment in Alzheimer’s disease, the 2-bromo-4-thiazolecarboxylic acid unit imparts a planar heterocyclic spacer that fills the S1–S3 subsite pocket and participates in edge-to-face π-stacking with Tyr71 of the enzyme. The synthetic strategy for this fragment requires compliance with ICH Q7 for low-volume clinical trial material manufacture, with particular attention to residual palladium and zinc speciation as required by the FDA IND program. In conjunction with EMA/CMDh/447045/2021, a nitrosamine risk assessment is mandatory: the route employs no secondary amines that could result in N-nitrosamine formation under the acidic conditions used downstream. The addition proportion in the pivotal Negishi cross-coupling between 2-bromo-4-thiazolecarboxylic acid and pre-formed 2-pyridylzinc bromide is set at 1.0:1.1 (acid to organozinc), employing 2 mol% Pd₂(dba)₃ and 8 mol% SPhos (2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl) in anhydrous THF at 25 °C for 90 min under argon. The 10% molar excess of organozinc compensates for homocoupling losses, and the post-reaction quenching with 10% aqueous NH₄Cl effectively removes zinc residues to <50 µg/g. Downstream, the reaction is filtered through a short plug of silica gel topped with thiol-functionalized silica (SilicaMetS‑Thiol) to scavenge palladium, then the filtrate is concentrated, diluted with isopropyl acetate, washed with brine, and polished by hot filtration at 45 °C to remove an amorphous impurity. The purified intermediate is then hydrogenolyzed (Pd/C, H₂ 1 atm) to remove the benzyl protecting group and coupled with a P3 amide surrogate. At the 50-kg manufacturing scale, the Negishi coupling is performed in a 400-L Hastelloy C-22 reactor jacketed with chilled water at 20–25 °C; the zinc reagent is freshly prepared by reacting 2-bromopyridine with Rieke zinc (pre-activated with TMSCl) in N,N-dimethylacetamide at 60 °C, then cooled and transferred via a 0.5-µm inline filter to avoid plugging by zinc dust. The final BACE1 inhibitor candidate (free base) is micronized and formulated as a 25 mg immediate-release tablet using direct compression with lactose monohydrate, microcrystalline cellulose, and crospovidone. The thiazolecarboxylic acid intermediate is susceptible to photodegradation: under ISO 10977:1996 testing conditions, exposure to 1.2 million lux·h of visible light results in 12% loss of assay due to debromination; therefore, all processing and storage must occur under amber glass and <100 lux yellow lighting. Furthermore, contact with stainless steel at temperatures above 50 °C for more than 24 h promotes corrosion-induced palladium deposition, so all batches are passivated with 20% nitric acid prior to use.